• Editorial Board

    May 21, 2026, 11:08

  • Syringe Services Participants’ Preferences for Wound Care, HIV/Hepatitis C Virus Screening, and Opioid Use Disorder Treatment: A Discrete Choice Experiment

    May 1, 2026, 00:00

  • Development of a Brief Personal Health Agency Measure Among Patients Seeking Discretionary Musculoskeletal Specialty Care

    May 1, 2026, 00:00

  • Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force

    May 1, 2026, 00:00

  • Valuing Child Health: An EQ-5D-Y-3L Value Set for the United States

    May 1, 2026, 00:00

  • Welfare-Based Healthcare Planning: Methodology and Application to Thoracic Surgical Treatment of Lung Cancer in Germany

    May 1, 2026, 00:00

  • Accounting for the Scarcity of Time as Patients Approach End of Life: The Construction of End-Weighted Time Toxicity

    May 1, 2026, 00:00

  • Estimating Heterogeneous Treatment Effects With Real-World Health Data: A Scoping Review of Machine Learning Methods

    May 1, 2026, 00:00

  • Estimating the Global Macroeconomic Impact of Tuberculosis Among Children and Adolescents

    May 1, 2026, 00:00

  • Influence of Initial Imaging Modality on Peri-Diagnostic Outcomes Among Pancreatic, Liver, Ovarian, and Bladder Cancers Without Routine Screening Programs: A Surveillance, Epidemiology, and End Results-Medicare Study

    May 1, 2026, 00:00

  • Assessing the Role of Presurgical Information on Patient-Reported Outcomes: A Causal Analysis

    May 1, 2026, 00:00

  • Table of Contents

    May 1, 2026, 00:00

  • No Differential Item Functioning of Patient-Reported Outcomes Measurement Information System Global Health Items by Neighborhood Socioeconomic Deprivation

    May 1, 2026, 00:00

  • Author Reply

    May 1, 2026, 00:00

  • Uncovering the Cost-Effectiveness of Theory-Based Implementation Approaches: A Health Economic Analysis of the Hide and Seek Project Trial

    May 1, 2026, 00:00

  • The Dark Side of the “Thousand-Faces” Vision: Ethical and Economic Reflections on Algorithmic Psychotherapy Matching

    May 1, 2026, 00:00

  • Technological Maturity and Cost-Effectiveness of Medical Artificial Intelligence: A Systematic Review of Health Economic Evaluations

    May 1, 2026, 00:00

  • Applying the Argument-Based Approach to Validation With Clinical Outcome Assessments: Strategies for Constructing a Rationale

    May 1, 2026, 00:00

  • Preferences for Neurodevelopmental Screening Modalities for Children: A Labeled Discrete Choice Experiment Using Partial Choice Set Design

    May 1, 2026, 00:00

  • International Reference Pricing: Impact of Changing the Basket of Reference Countries on Ability to Reference and on Drug Launch Prices in 6 Markets

    May 1, 2026, 00:00

  • A United Kingdom Value Set for the EQ-5D-5L

    May 1, 2026, 00:00

  • Optimizing Decision Making in Universal Newborn Hearing Screening: A Value of Information Perspective

    May 1, 2026, 00:00

  • From Prediction to Optimization: Machine Learning-Driven Integration of the Health Economic Value Chain and Revolution in System Efficiency

    May 1, 2026, 00:00

  • Switching From EQ-5D-3L to EQ-5D-5L in England: The Impact in NICE Technology Appraisals

    May 1, 2026, 00:00

  • A Practical Method for Estimating Generalized Risk-Adjusted Cost-Effectiveness Utilities and Willingness-to-Pay Corrections

    May 1, 2026, 00:00

  • Editorial Board

    Apr 6, 2026, 13:15

  • Face Validation of an Artificial Intelligence Driven Tool for Clinical Triaging in Australian Public Oral Healthcare: A Pilot Study

    Apr 1, 2026, 00:00

  • How Good Is Good Enough? A Simulation Study of Adaptive Health Technology Assessment

    Apr 1, 2026, 00:00

  • A Forward Agenda for Digital Health Technologies: Evidence That Works for Decisions

    Apr 1, 2026, 00:00

  • A Systematic Review of the Methods and Quality of Economic Evaluations for Artificial-Intelligence-Assisted Cancer Screening or Diagnosis

    Apr 1, 2026, 00:00

  • Reanalyzing Value Assessments in American Heart Association Clinical Practice Guidelines Using Health Years in Total Instead of Quality-Adjusted Life-Years

    Apr 1, 2026, 00:00

  • Valuing Pediatric Technologies: A Framework for Parental Spillovers in Spinal Muscular Atrophy Bereavement

    Apr 1, 2026, 00:00

  • Exploring Methods to Include Carbon Emissions Into a Health Technology Assessment: The Case of Remote Patient Monitoring

    Apr 1, 2026, 00:00

  • Table of Contents

    Apr 1, 2026, 00:00

  • Implications of Incorporating Environmental Sustainability Into Health Technology Assessment for Digital Health Technologies

    Apr 1, 2026, 00:00

  • Impact of Heatwaves on Health-Related Quality of Life in Older Chinese Adults: A Longitudinal Cohort Study

    Apr 1, 2026, 00:00

  • Estimating the Shares of the Value of Branded Pharmaceuticals Accruing to Manufacturers and to Patients in the Thai Healthcare System

    Apr 1, 2026, 00:00

  • Qini Curves for Potential Impact Assessment of Risk Predictive Models Informing Intervention Policies

    Apr 1, 2026, 00:00

  • Author Reply

    Apr 1, 2026, 00:00

  • Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis

    Apr 1, 2026, 00:00

  • From Consensus to Implementation: Advancing Patient-Centered Health Technology Assessment

    Apr 1, 2026, 00:00

  • Evaluation of Health Technology Assessment Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access

    Apr 1, 2026, 00:00

  • Author Reply

    Apr 1, 2026, 00:00

  • Cost Savings and Improved Clinical Outcomes From a Mobile Health Cardiovascular Disease Self-Management Program

    Apr 1, 2026, 00:00

  • Toward a Harmonized Health Technology Assessment Framework for Digital Health Technologies in Europe

    Apr 1, 2026, 00:00

  • System-Wide Use of Patient-Reported Outcome Measures in Organization for Economic Co-operation and Development Countries: Insights From a Health Policy Survey and Key Informant Workshops

    Apr 1, 2026, 00:00

  • The Effect of Perspective, Duration, and Views on Death on the Valuation of Severe Health States

    Apr 1, 2026, 00:00

  • Deepening and Broadening: Revisiting Theories, Long-Term Economic Impact, and Diversity in Parental Bereavement After the Loss of a Child to Spinal Muscular Atrophy

    Apr 1, 2026, 00:00

  • Valuing Child and Adolescent Health States to Derive Utilities for Use in Economic Evaluation: A Good Practices Report of an ISPOR Task Force

    Apr 1, 2026, 00:00

  • Decision Analytic Models to Assess the Cost-Effectiveness of Prevention, Detection, and Treatment in Multiple Long-Term Conditions: A Scoping Review

    Apr 1, 2026, 00:00

  • A Patient-Level Simulation Tool to Inform Data-Driven Pain Treatment Decisions and Policy in the US Military Health System

    Apr 1, 2026, 00:00

  • Editorial Board

    Mar 11, 2026, 10:20

  • Health Utility Decrements Associated With Social Isolation and Loneliness: Evidence From Australian Longitudinal Data

    Mar 1, 2026, 00:00

  • Psychometric Performance of Skin, Self-Confidence, and Social Health-Related EQ-5D-5L Bolt-Ons in Patients With Atopic Dermatitis and Psoriasis in Germany

    Mar 1, 2026, 00:00

  • Reversing Proxy Roles: Care Recipients as Proxies for Caregiver Health-Related Quality of Life

    Mar 1, 2026, 00:00

  • Author Reply

    Mar 1, 2026, 00:00

  • Psychometric Properties of Cognition Bolt-Ons for the EQ-5D-3L and EQ-5D-5L: A Systematic Review

    Mar 1, 2026, 00:00

  • Empirical Evidence and Conceptual Framework to Address the Indian Health Service Underfunding Challenge

    Mar 1, 2026, 00:00

  • Disinvestment and Health Spending Efficiency in Latin America and the Caribbean: A Case Study of Colombia

    Mar 1, 2026, 00:00

  • The Uneven Path of Psychological Distress: How Socioeconomic Status Shapes Distress Transitions in Australian Adults

    Mar 1, 2026, 00:00

  • Priority for Self or Others? Incorporating Equity Considerations in a Preference-Based Health Value Assessment

    Mar 1, 2026, 00:00

  • Patient-Reported Outcome Measures in Clinical Trials: An Analysis of Trends From 2008 to 2023

    Mar 1, 2026, 00:00

  • Impact of China’s National Drug Price Negotiation Policy on Availability, Affordability, and Regional Equity of Negotiated Drugs: A Multidimensional Nationwide Analysis, 2018 to 2021

    Mar 1, 2026, 00:00

  • Genomic Testing in Australia: A Budget Impact Analysis Using Diffusion Modeling From a Healthcare System Perspective

    Mar 1, 2026, 00:00

  • The Compounding Burden of Pregnancy Loss: A Longitudinal Analysis of Quality-of-Life Trajectories After Miscarriage

    Mar 1, 2026, 00:00

  • Evaluating Long-Term Health Disparity Impacts of Clinical Algorithms Using a Patient-Level Simulation Framework

    Mar 1, 2026, 00:00

  • Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care, and Well-Being Measures in the Context of Multiple Sclerosis

    Mar 1, 2026, 00:00

  • Economic Evaluation of Deprescribing in Older Adults: A Systematic Review

    Mar 1, 2026, 00:00

  • Table of Contents

    Mar 1, 2026, 00:00

  • Quantifying Accuracy and Cost in Public Preferences for Artificial Intelligence in Radiation Therapy

    Mar 1, 2026, 00:00

  • Comparative Effectiveness of Ixekizumab Versus Ustekinumab in Patients With Psoriasis: A Randomized Controlled Trial Replication Using Data From an Observational Study (Shanghai Psoriasis Effectiveness Evaluation Cohort)

    Mar 1, 2026, 00:00

  • Estimating the Willingness-to-Pay per Quality-Adjusted Life-Year to Aid Health Technology Assessment in India

    Mar 1, 2026, 00:00

  • Return-on-Investment in Health Economic Evaluation: An Exploratory Analysis

    Mar 1, 2026, 00:00

  • Long-Term Outcomes and Cost-Effectiveness of Artificial Intelligence for Breast Cancer Screening: A Modeling Study

    Feb 1, 2026, 00:00

  • How Do Different Health States Impact Preferences for Social-Care-Related Quality of Life: An Exploration of EQ-5D-5L and Adult Social Care Outcomes Toolkit Using a Vignette Approach

    Feb 1, 2026, 00:00

  • Cost-Effectiveness of Reorganizing the Approach to Diabetes Through the Application of Registries: An Innovative Model to Organize Diabetes Care in First Nations Communities in Canada

    Feb 1, 2026, 00:00

  • Development of a Preference Weighting System for the Parent-Proxy Child Chronic Cough Quality-of-Life Instrument

    Feb 1, 2026, 00:00

  • Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Special Interest Group Report

    Feb 1, 2026, 00:00

  • A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making

    Feb 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children With Asthma

    Feb 1, 2026, 00:00

  • Preferences for Adopting Artificial Intelligence in Radiation Therapy Treatment: A Discrete Choice Experiment

    Feb 1, 2026, 00:00

  • Means Can Be Deceiving: Comparing and Contrasting Risk Tolerance Estimates From a Discrete-Choice Experiment and a Threshold Technique Exercise

    Feb 1, 2026, 00:00

  • Derivation of Meaningful Change Thresholds for European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 in Patients With Small-Cell Lung Cancer

    Feb 1, 2026, 00:00

  • Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular Atrophy

    Feb 1, 2026, 00:00

  • PROM-ising Progress? Trends in Patient- and Clinician-Reported Outcome Measures in US Food and Drug Administration Orphan Drug Labels

    Feb 1, 2026, 00:00

  • Mapping Methodologies for Economic Evaluation of Digital Health Technologies: A Scoping Review

    Feb 1, 2026, 00:00

  • EQ-5D-5L in Multiple Sclerosis: Estimated Utility Values, Minimal (Clinically) Important Changes, and Direct and Indirect Influences Over Time

    Feb 1, 2026, 00:00

  • Should Early-Stage NIH Funding Influence Pharmaceutical Drug Pricing?

    Feb 1, 2026, 00:00

  • What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective

    Feb 1, 2026, 00:00

  • Hospital and Regional-Level Factors Associated With Negotiated Payer Rates for Hip Fracture Fixation: A Multistate Analysis

    Feb 1, 2026, 00:00

  • Comparing Psychometric Properties of 6 of the 5-Level and 3-Level EQ-5D Bolt-Ons in a Large, Multinational, Longitudinal General Population Sample

    Feb 1, 2026, 00:00

  • The Cost-Effectiveness of Community Health Workers in Primary Health Care: A Systematic Review

    Feb 1, 2026, 00:00

  • Editorial Board

    Jan 23, 2026, 08:45

  • Table of Contents

    Jan 23, 2026, 08:41

  • Table of Contents

    Jan 5, 2026, 12:03

  • Methodological Insights From Health Valuation Studies in Low- and Middle-Income Countries: A Scoping Review

    Jan 1, 2026, 00:00

  • Operationalizing Distributional Cost-Effectiveness in Genomic Medicine: A United States–Focused Comment

    Jan 1, 2026, 00:00

  • Incorporating Informal Caregiving Time Into Cost-Effectiveness Analysis for Adults Aged 50 and Older: Estimating From Health-Related Quality of Life and Functional Status

    Jan 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children Aged 8 to 18 Years With Eczema

    Jan 1, 2026, 00:00

  • Predicting Healthcare Utilization Outcomes With Artificial Intelligence: A Large Scoping Review

    Jan 1, 2026, 00:00

  • The Cost-Effectiveness of Collagenase Injection Versus Limited Fasciectomy for Moderate Dupuytren’s Contracture: An Economic Evaluation of the Dupuytren’s Interventions Surgery Versus Collagenase Trial and a Decision Analytical Model

    Jan 1, 2026, 00:00

  • Health Inequality Aversion in the United States

    Jan 1, 2026, 00:00

  • Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program

    Jan 1, 2026, 00:00

  • Comparing Adolescent and Adult Preferences for EQ-5D-Y-3L Health States in Hong Kong

    Jan 1, 2026, 00:00

  • Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds

    Jan 1, 2026, 00:00

  • Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries

    Jan 1, 2026, 00:00

  • Adult Social Care Outcomes Toolkit and ICEpop Capability Measure in Decision Making: A Review of NICE Social Care and Public Health Guidelines

    Jan 1, 2026, 00:00

  • Unlocking Patient Preferences: The Potential of Stated-Preference Methods in Clinical Decision Making

    Jan 1, 2026, 00:00

  • Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions

    Jan 1, 2026, 00:00

  • A Generalized Risk-Adjusted Cost-Effectiveness Economic Model for Measuring the Value of Interventions That Delay Mobility Impairment Across Neurological Conditions

    Jan 1, 2026, 00:00

  • Implications of Value Set Choice on EQ-5D-Y-3L Child and Proxy Health-Related Quality of Life Ratings: What to Do When a Country-Specific “Y” Value Set Is Unavailable?

    Jan 1, 2026, 00:00

  • Integrating Price Benchmarks and Comparative Clinical Effectiveness to Predict Initial Price Offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027)

    Jan 1, 2026, 00:00

  • Clinical Outcomes and Measures for Vaginal Relaxation Syndrome: A Systematic Review

    Jan 1, 2026, 00:00

  • Toward a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report

    Jan 1, 2026, 00:00

  • Editorial Board

    Jan 1, 2026, 00:00

  • Disclaimer

    Dec 19, 2025, 11:50

  • Editorial Board

    Dec 16, 2025, 09:49

  • EE328 Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework

    Dec 1, 2025, 00:00

  • RWD68 Economic and Clinical Burden of MACE-Related Rehospitalizations in Patients With Obesity: A Real-World Study Based on Italian Healthcare Data

    Dec 1, 2025, 00:00

  • PCR84 Evaluating the Role of Patient-Reported Outcomes in Phase 4 Clinical Trials: Trends, Applications, and Implications for Postmarketing Surveillance

    Dec 1, 2025, 00:00

  • EE125 Climate Impact of CAR-T Cell Therapy in the Netherlands: A Comparison on the Use Phase Emission Between Standard of Care and CAR-T Cell Therapy in Hemato-oncology

    Dec 1, 2025, 00:00

  • EE676 Surviving but Not Earning? Long-term Income Trajectories in Working-Age mIDH Glioma Patients: Stratification by Radiotherapy/Chemotherapy Exposure

    Dec 1, 2025, 00:00

  • CO263 Utility Values From Pooled Analysis of High Concentration (179 mg) Capsaicin Patch (HCCP) Studies In Peripheral Neuropathic Pain (PNP)

    Dec 1, 2025, 00:00

  • EE737 Treatment Patterns of Rare Immunodeficiencies With Special Regard to Antibiotics: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • HTA146 Exploring Nordic Real-World Evidence Sources for a PICO Assessment of a Hypothetical Oncology Drug and Medical Device Product

    Dec 1, 2025, 00:00

  • CO40 Characterization of the Distribution of Body Mass Index in Portuguese People With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • EE303 Cost-Utility Analysis of Iptacopan vs. C5 Inhibitors in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Naïve to Complement Inhibitors in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • HTA96 Cost-Effectiveness Assessment of Orphan Drugs in Fran Key Insights from CEESP Reviews (2021-2024)

    Dec 1, 2025, 00:00

  • EPH34 Burden of Hospitalized Viral Respiratory Infections in Fran Insights From the 2022-2023 Season

    Dec 1, 2025, 00:00

  • EPH193 Prevalence of Post-Traumatic Stress Disorder Among Ambulance Officers During the COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • HSD67 Knowledge and Practices Regarding Expired Medications Among Saudi Citizens

    Dec 1, 2025, 00:00

  • MSR95 Evaluating the Performance of a Supervised Artificial Intelligence Model in Screening Abstracts for Oncology-Focused Targeted Literature Reviews

    Dec 1, 2025, 00:00

  • CO195 Qualitative Exit Interviews in Charcot-Marie-Tooth Type-2 Sorbitol Dehydrogenase (CMT-SORD) Deficiency

    Dec 1, 2025, 00:00

  • HTA361 What Did Time Reveal Evaluating the Accuracy of Parametric Model Predictions Against Long-Term Observed Data for Larotrectinib?

    Dec 1, 2025, 00:00

  • PT42 Comparative Effectiveness of Second-Line Antidiabetic Medications on the Risk of Major Adverse Cardiovascular Events: A Real-World Study in China

    Dec 1, 2025, 00:00

  • MSR1 A Comparison of Methods for Missing Covariates in a Meta-Regression Using Data From a Systematic Review on Oral Epithelial Dysplasia

    Dec 1, 2025, 00:00

  • HPR164 Prices And Reimbursement Conditions for Poly (ADP-RIBOSE) Polymerase Inhibitors (PARPi) Indicated for Ovarian Cancer in Spain

    Dec 1, 2025, 00:00

  • CO202 Real-World Effectiveness of Oral Semaglutide in Thai Patients With Type 2 Diabetes: An Observational Single-Arm Multicenter Retrospective Cohort Study (REALISED)

    Dec 1, 2025, 00:00

  • HTA325 The Perils of Treatment Crossover in Clinical Trials

    Dec 1, 2025, 00:00

  • PCR263 Valuing Health States When Transitioning From Stage 2 to Stage 3 Type 1 Diabetes in a Sample of the General Population in the United Kingdom

    Dec 1, 2025, 00:00

  • MT12 Cost Impact of the Porcine Urinary Bladder Matrix in Patients With Diabetic Foot Ulcer in the United Kingdom

    Dec 1, 2025, 00:00

  • HPR119 Implementing Coverage With Evidence Development for Medicines With Uncertain Clinical Benefit: Insights From the Netherlands

    Dec 1, 2025, 00:00

  • HPR197 The Disease Burden of Respiratory Syncytial Virus Among the Adult Population in Greece

    Dec 1, 2025, 00:00

  • MT43 Unlocking Value Early: Insights Into NICE’s Early Value Assessments and Evidence-Generation Plans for Medical Technologies

    Dec 1, 2025, 00:00

  • EE450 Evolving Payer Preferences for Health Economic Information and Communication in the US

    Dec 1, 2025, 00:00

  • HTA86 Comprehensive Clinical Evaluation of Amphotericin B in the Treatment of Invasive Fungal Disease in China

    Dec 1, 2025, 00:00

  • EE54 Application and Future Potential of Generative Artificial Intelligence (Gen AI) And Large Language Model (LLM) In Health Economics and Outcomes Research (HEOR)

    Dec 1, 2025, 00:00

  • EE32 A Systematic Literature Review of Cost of Illness Studies on Atrial Fibrillation With Focus on the Methodologies Economic Burden and Factors Influencing the Cost of Atrial Fibrillation Among European and North American Countries

    Dec 1, 2025, 00:00

  • HPR222 Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-offs

    Dec 1, 2025, 00:00

  • HTA139 Evolution of Acceptance of Evidence and PMA Outcomes by HTA Authorities for ATMPs in the EU4 and the UK 2017-2025

    Dec 1, 2025, 00:00

  • PT13 Mapping the Measurement Gap: Patient-Reported Outcomes Across the Obesity Care Continuum in the GLP-1 Era

    Dec 1, 2025, 00:00

  • EE368 Economic Burden Utilities and Cost-Effectiveness of the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • CO225 Systematic Literature Review (SLR) of Efficacy, Health-Related Quality of Life (HRQoL), and Safety of the First-Line (1L) Treatments of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Dec 1, 2025, 00:00

  • EPH172 Objective Real-World Caregiver Costs and Lost Time for Absences and Family Medical Leaves in the United States for Employees Whose Spouses Have Dementia and/or Alzheimer’s Disease and Patient Direct Costs

    Dec 1, 2025, 00:00

  • EE576 Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment

    Dec 1, 2025, 00:00

  • MSR197 The Effects of Pooling Treatment Effects Targeting Treatment Policy and Hypothetical Estimands With Rank-Preserving Structural Failure Time Model in Oncology Aggregate-Level Meta-Analyses

    Dec 1, 2025, 00:00

  • MSR43 Automation-Only Is NOT AI: Beware, HEOR Colleagues

    Dec 1, 2025, 00:00

  • MSR217 Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-Term Treatment Effect: An Example in Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • HTA170 Have Delays in Vaccine Market Access Improved in Europe and the US Over the Last Decade?

    Dec 1, 2025, 00:00

  • MSR51 Can an Ensemble Machine-Learning Approach Outperform Traditional Models While Enhancing Accuracy, Fairness, and Interpretability in Clinical Risk Prediction?

    Dec 1, 2025, 00:00

  • PCR33 Bimekizumab Led to Sustained Improvements in Health-Related Quality of Life and Work Productivity in Patients With Axial Spondyloarthritis: 3-Year Results From Two Phase 3 Studies

    Dec 1, 2025, 00:00

  • HPR14 Access and Evolving Eviden A European HTA Analysis of Innovative Medicines Under Evidence Generation Agreements

    Dec 1, 2025, 00:00

  • HTA137 Evidence of Mapping Malpractice? A Review of Mapping Algorithm Usage in NICE Health Technology Appraisals

    Dec 1, 2025, 00:00

  • PCR65 Diagnostic Odyssey of Patients With the Rare Immunodeficiency-Activated PI3 Kinase Delta Syndrome (APDS): Case Study With Expert Interviews and Patient Surveys

    Dec 1, 2025, 00:00

  • P53 Exploring the Ability of Generative AI to Interpret and Report Comprehensive NMA Results: A Step Towards the Automation of NMA Reports

    Dec 1, 2025, 00:00

  • CO102 Estimating the Mean Time in Treatment-Free Remission for Patients in Early Line CML

    Dec 1, 2025, 00:00

  • HTA130 Evaluating Clinical Similarity: A Systematic Review of Methods Used Within National Institute for Health and Care Excellence (NICE) Cost-Comparison Evaluations (CCEs) When Relying on Statistically Nonsignificant Differences From Indi ...

    Dec 1, 2025, 00:00

  • EE250 Cost-Effectiveness of Familial Hypercholesterolemia Cascade Testing in Thailand: A Comparative Analysis of Exome vs. Long-Read DNA Sequencing

    Dec 1, 2025, 00:00

  • EE158 Cost Calculator of Immunotherapies in 1L Endometrial Cancer Treatment for the Deficient Mismatch Repair, Proficient Mismatch Repair, and Intention-to-Treat Populations From the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • CO12 APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes

    Dec 1, 2025, 00:00

  • HTA249 Navigating the Transition: What EU JCA Means for AMNOG Submissions in 2025 and Beyond

    Dec 1, 2025, 00:00

  • EPH216 Social Inequality in the Uptake of Varicella Vaccination: A Danish Nationwide Observational Study

    Dec 1, 2025, 00:00

  • HTA161 German Early Benefit Assessments and the Impact of Medical Societies: An Analysis

    Dec 1, 2025, 00:00

  • MSR161 Overfitting Mitigation in Neural Networks: Could Ergodic Regularization Be the Future of AI?

    Dec 1, 2025, 00:00

  • EE473 First-Line Immunotherapies for Advanced Biliary Tract Cancer: A Systematic Review of Economic Studies

    Dec 1, 2025, 00:00

  • EPH194 Productivity Costs Due to Respiratory Infections in Denmark: A Potential for Prophylaxis

    Dec 1, 2025, 00:00

  • PCR172 Patient Involvement in the Development of Obesity and Weight Loss-Specific Patient-Reported Outcome Measures

    Dec 1, 2025, 00:00

  • EE143 Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain

    Dec 1, 2025, 00:00

  • MSR227 Zoom Out: Simplifying Complex Health Economic Model Structure Through Artificial Intelligence

    Dec 1, 2025, 00:00

  • EE436 Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands

    Dec 1, 2025, 00:00

  • HTA286 Reimbursement Trends for Advanced Therapeutic Medicinal Products (ATMPs) in Europe

    Dec 1, 2025, 00:00

  • RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care

    Dec 1, 2025, 00:00

  • SA36 Economic Burden Utilities and Cost-Effectiveness of Perioperative Immunotherapies for Early Stage Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • MSR224 Which Generative AI Method Is Used for High Specificity? A Methodological Comparison From the Systemic Literature Review of the Burden of Influenza in France

    Dec 1, 2025, 00:00

  • HPR25 Analysis of the Impact of the TelE-Medicine Program for Medically Underserved Area on Hospitalization Rates Among Diabetic Patients in Medically Underserved Areas

    Dec 1, 2025, 00:00

  • P4 Simulating Sponsor-HTA Conversations: A Multi-Agent GenAI Framework for Reimbursement Processes

    Dec 1, 2025, 00:00

  • RWD60 Development and Implementation of a Dynamic Framework for Assessment and Improvement of Registries’ Data Quality

    Dec 1, 2025, 00:00

  • MSR127 Implementing Simultaneous Maximum Acceptable Risk Thresholds (SMARTs) in Discrete Choice Experiments (DCE): A Feasible Approach to Quantify Tolerance for Multiple Risks

    Dec 1, 2025, 00:00

  • HTA44 Assessing Readiness for the EU-HTA Regulation: Insights From Market Access Experts Across Europe

    Dec 1, 2025, 00:00

  • EPH130 Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends

    Dec 1, 2025, 00:00

  • HTA32 Analysis of Pros Included in the HTA Assessment of Conditionally Approved Oncology Drugs in the UK, Italy, and Germany

    Dec 1, 2025, 00:00

  • EE535 Impact of Indirect Treatment Comparison (ITC) Methodology on Cost-Effectiveness of Quizartinib in Acute Myeloid Leukemia (AML) in Canada and the United Kingdom (UK)

    Dec 1, 2025, 00:00

  • EE45 An Early Cost-Effectiveness Model for a Digital Community-Based Approach for Streamlined Audiology Care

    Dec 1, 2025, 00:00

  • HTA362 What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques

    Dec 1, 2025, 00:00

  • HTA219 Level of ICER of Health Economic Assessment in France in 2024

    Dec 1, 2025, 00:00

  • CO158 Leveraging Generative AI for Efficient Patient Safety Narrative Drafting: A Semaglutide Case Study

    Dec 1, 2025, 00:00

  • EPH140 Incidence and Prevalence of Primary Biliary Cholangitis (PBC) and Cholestatic Pruritus (CP) in Germany: Results From a Statutory Health Insurance (SHI) Claims Analysis

    Dec 1, 2025, 00:00

  • HSD43 Environmental Impact of Intravenous vs. Oral Chemotherapy in Fran A 1000-Patient Model-Based Assessment

    Dec 1, 2025, 00:00

  • HSD97 Real-World Treatment Patterns Among Patients With Relapsed or Refractory (R/R) NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US)

    Dec 1, 2025, 00:00

  • EE351 Economic and Social Burden of Pulmonary Hypertension in Italy

    Dec 1, 2025, 00:00

  • EPH239 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Squamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • PCR32 Bimekizumab Improves Work Productivity in Patients With Hidradenitis Suppurativa: 2-Year Results From BE HEARD EXT

    Dec 1, 2025, 00:00

  • PCR180 Patient Preferences for Type 2 Diabetes Mellitus (T2DM) Treatment: A Systematic Review of Discrete Choice Experiments Studies

    Dec 1, 2025, 00:00

  • HSD116 Treatment Patterns, Inadequate Disease Control, and Burden/Unmet Need Among Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program

    Dec 1, 2025, 00:00

  • EE501 Healthcare Costs of Mammography Screening and Breast Cancer Treatment: A Registry-Based Study From Norway

    Dec 1, 2025, 00:00

  • EE620 Projected Public Health Impact of Synchronized COVID-19 and Influenza Vaccination With a Combination Vaccine in US Older Adults

    Dec 1, 2025, 00:00

  • HPR19 Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis

    Dec 1, 2025, 00:00

  • HTA6 A Decade in Decision Making: Reviewing Trends in STAS by NICE in Different Disease Areas

    Dec 1, 2025, 00:00

  • HSD122 Utilization of Informal WhatsApp for Pre- and Postnatal Referral Services in the Kwadaso Municipality of Ghana

    Dec 1, 2025, 00:00

  • EE425 Estimating the Cost-Effectiveness of Tumor-Treating Fields With Gemcitabine and Nabpaclitaxel for Frontline Treatment of Locally Advanced Pancreatic Adenocarcinoma

    Dec 1, 2025, 00:00

  • HTA54 Beyond RCTs: The Role of Patient Perspectives and Nontraditional Evidence in HTA Decisions for Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • HTA55 Beyond the QALY: An Analysis of Uncaptured Benefits in NICE Oncology Technology Appraisals 2023-2025

    Dec 1, 2025, 00:00

  • EE528 Impact of Comparator Type on Cost-Effectiveness Outcomes: Insights From ASMR III Evaluations in France

    Dec 1, 2025, 00:00

  • HPR74 European and US Drug Shortages: A Critical Analysis of Key Trends and Causes

    Dec 1, 2025, 00:00

  • HPR134 Maintaining Orphan Drug Status at the Time of Drug Approval in European Economic Area (EEA): European Union (EU) Plus Iceland and Norway From 2015 to 2025

    Dec 1, 2025, 00:00

  • P16 Beyond PFS and OS: Recovering Pre- and Post-Progression Survival From Survival Curves

    Dec 1, 2025, 00:00

  • HPR82 Evolution of Negotiations and Contracts for Reimbursement of Pharmaceuticals in Greece Between 2020 and 2025: Onwards and Upwards

    Dec 1, 2025, 00:00

  • EE120 Can Intravitreal Aflibercept 8 mg Result in Decreased Treatment Burden and Treatment Costs in European Patients With Age-Related Macular Degeneration? Early Evidence From Clinical Practice

    Dec 1, 2025, 00:00

  • PCR257 Uptake and Early Removal of Hormonal Implant Contraceptive Among Women Attending the Family Planning Clinic in a Tertiary Institution in West Africa January 2018-December 2020

    Dec 1, 2025, 00:00

  • RWD146 Real-World Adherence to Nonhormonal Therapies for Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • MSR167 Piloting a GenAI Agent for Structured Quality Appraisal of Network Meta-Analyses Using the ISPOR-AMCP-NPC Checklist

    Dec 1, 2025, 00:00

  • CO34 Budget Impact of a PreTRM-Guided Preventive Bundle for Preterm Birth in Low-Risk Pregnancies: A Microsimulation Study Using PRIME Trial Data

    Dec 1, 2025, 00:00

  • CO128 Health Technology Assessment, Reimbursement, and Funding Landscape Challenges for Oncology Companion Diagnostics in Europe and Canada

    Dec 1, 2025, 00:00

  • EPH75 Epidemiological Characteristics and Economic Burden of IgA Nephropathy—a Retrospective Study Using Multicenter Electronic Medical Records Data in China

    Dec 1, 2025, 00:00

  • HPR205 The Implementation of the European Charter of Patients’ Rights in Hungarian and Romanian Healthcare Legislation With Special Emphasis on Informed Consent

    Dec 1, 2025, 00:00

  • CO49 Clinical Outcomes In HTA Appraisal Reports Of Oncology Medicines In Portugal: A Cross-Sectional Analysis

    Dec 1, 2025, 00:00

  • P5 The Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) in the US: A Total System Value Evidence Framework

    Dec 1, 2025, 00:00

  • MSR146 Metamodels SHAP Analysis: Unearthing Data Interactions

    Dec 1, 2025, 00:00

  • PCR195 Psychometric Evaluation of the Impact of Weight on Quality of Life–Lite Clinical Trials (IWQOL-Lite-CT) Version in Adults Participating in a Pharmacological Clinical Trial for Obesity

    Dec 1, 2025, 00:00

  • HTA352 Using External Clinical Evidence to Inform Local Health Policy: The Tradeoff Between Early Access and Uncertainty

    Dec 1, 2025, 00:00

  • EE377 Economic Evaluation of Cefiderocol for the Treatment of Confirmed MBL-Producing Pathogens in Italy

    Dec 1, 2025, 00:00

  • CO24 Balancing Innovation and Propriety: The Question of Copyright Holder’s Opinions on GenAI Usage While Localizing Their Intellectual Property

    Dec 1, 2025, 00:00

  • SA60 Let LAMBA Do the Work: Can We Reduce Reliance on VBA in Health Economic Models?

    Dec 1, 2025, 00:00

  • EE40 Adherence to Guidelines for the Treatment of Diabetes With Modern Antidiabetic Drugs in the Czech Republic: Clinical and Economic Impacts

    Dec 1, 2025, 00:00

  • HPR194 The Clawbacks Paradox: When Abusing a Simple Approach Has the Most Complicated and Problematic Consequences for Patients and Healthcare Systems

    Dec 1, 2025, 00:00

  • MT38 Standardizing Healthtech Evidence to Meet NICE Expectations

    Dec 1, 2025, 00:00

  • CO156 Investigating Composite Response Definitions Based on Key Surrogate Markers for Predicting Clinical Outcomes in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EE589 Modeling the Healthcare Burden of Oral Corticosteroid Use in Mexico

    Dec 1, 2025, 00:00

  • EE348 Early Stage Health Economic Evaluation of IMMUTOL Gene Therapy for Relapsing/Remitting Multiple Sclerosis in the Netherlands

    Dec 1, 2025, 00:00

  • MSR101 Excel Front-End, R Back-End: A Gateway to Faster Individual Patient Simulations and Probabilistic Sensitivity Analyses in Cost-Effectiveness Models for HTA

    Dec 1, 2025, 00:00

  • MSR41 Assessing the Psychometric Performance of the Experimental EQ-TIPS V20 in Assessing the Health-Related Quality of Life of Stunted Children in Laos

    Dec 1, 2025, 00:00

  • HTA355 Value Framework to Support Payer Decisions in Hemophilia in Türkiye

    Dec 1, 2025, 00:00

  • MT16 Evaluating Digital Health Tools in the UK for Type 1/2 Diabetes: An Overview of the Evidence Critiques

    Dec 1, 2025, 00:00

  • EE599 Optimization of the EVAR Pathway: An Integrated Organizational Model for Clinical Efficiency and Economic Sustainability

    Dec 1, 2025, 00:00

  • HTA38 Are Real-World Survival Outcomes in Metastatic Breast Cancer Transportable Between the US and Austria?

    Dec 1, 2025, 00:00

  • CO212 Resistance-Driven Treatment Failure: A Challenge to HCV Elimination in Pakistan

    Dec 1, 2025, 00:00

  • MT5 Artificial Intelligence in Health Economics: Opportunities and Challenges for the Future: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA91 Correlation of Intermediate Clinical Endpoints (ICES) For Overall Survival (OS) In Localized or Locally Advanced Prostate Cancer (LPC/LAPC): Analysis of Individual Real-World Data (RWD)

    Dec 1, 2025, 00:00

  • EPH85 Estimating Rare Disease Incidence and Prevalence of Essential Thrombocythemia in Major Health Plans in the United States

    Dec 1, 2025, 00:00

  • CO171 NMAs of Systemic Therapies for Advanced Biliary Tract Cancer: A Systematic Review and Critical Appraisal Using RoB NMA

    Dec 1, 2025, 00:00

  • OP23 Streamlining Cancer Treatment Pathways: Organizational Responses to Rising Chemotherapy Volumes

    Dec 1, 2025, 00:00

  • OP9 Gatekeepers of Scien Evolving Publishing Policies in the Age of AI

    Dec 1, 2025, 00:00

  • RWD125 Millennial Medical Record (MMR) Data Profile: A Japanese Electronic Medical Records (EMRs) Database Utilizing Unstructured Data for Lung Cancer Research

    Dec 1, 2025, 00:00

  • HTA164 Get JCA-Ready: Mastering PROs for Market Access Success

    Dec 1, 2025, 00:00

  • EE590 Modeling Treatment-Free Remission Outcomes for Asciminib in Newly Diagnosed Chronic Myeloid Leukemia: Assumptions, Methodology, and Projections

    Dec 1, 2025, 00:00

  • HTA67 CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?

    Dec 1, 2025, 00:00

  • PCR129 Impact of Glucagon-Like Peptide-1 Treatments on Patient-Reported Outcomes in Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • EE226 Cost-Effectiveness and Impact of Nirmatrelvir/Ritonavir in Reducing Hospitalizations Among Elderly COVID-19 Patients in Sweden

    Dec 1, 2025, 00:00

  • HTA124 Enhancing Patient Involvement in European Health Technology Assessment (HTA): From Inconsistent National Practices to Systematic Engagement in Joint Clinical Assessments

    Dec 1, 2025, 00:00

  • PCR34 Burden of Transfusion in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Results From a Real-World Study in European Countries

    Dec 1, 2025, 00:00

  • HPR160 Physicians' and Pharmacists’ Views on Implementing Generic Medicines Standard and Biosimilar Guide

    Dec 1, 2025, 00:00

  • MT21 Generative A-Powered Extraction of Immune-Related Adverse Events From Oncology Case Reports

    Dec 1, 2025, 00:00

  • SA83 Real-World Utilization Patterns of Corticosteroids in Ulcerative Colitis: Prevalence of Excessive Use in Routine Clinical Practice

    Dec 1, 2025, 00:00

  • EE426 Estimating the Economic Burden of DLBCL: Developing and Testing a Cost of Disease Model

    Dec 1, 2025, 00:00

  • HPR155 Patient-Reported Outcomes Used for Regulatory Approval of Oncology Medicinal Products in the European Union Between 2021 and 2024: A Review Update

    Dec 1, 2025, 00:00

  • HTA225 LLM Engineering in HEOR: Approaches to Improving Accuracy in Clinical Data Extraction

    Dec 1, 2025, 00:00

  • EE221 Cost-Effectiveness Analysis of the Prostate Health Index (PHI) Test After a Prostate-Specific Antigen (PSA) Test in UK

    Dec 1, 2025, 00:00

  • CO107 Evaluating the Health Impact of Anti-PD-(L)1 Agents for Early Stage Cancer Treatment in the Czech Republic

    Dec 1, 2025, 00:00

  • EE55 Assessing Conditional Cash Transfers for Tuberculosis Patients in India: An Extended Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • HSD18 Burden of In-Clinic and At-Home Administration of Injectable Biologics for Severe Asthma and Chronic Rhinosinusitis With Nasal Polyps: Interim Results From a Time and Motion Study

    Dec 1, 2025, 00:00

  • PCR231 The Impact of Inhaler Technique on the Health Outcomes and Cost Among Adults With Asthma and Chronic Obstructive Pulmonary Disease in Saudi Arabia

    Dec 1, 2025, 00:00

  • HSD4 Advancing Real-World Evidence in Diffuse Large B-cell Lymphoma: Insights From EHR-Derived Data in the UK

    Dec 1, 2025, 00:00

  • EE258 Cost-Effectiveness of Levofloxacin for Tuberculosis Prevention in MDR/RR-TB Contacts in High-Burden Settings

    Dec 1, 2025, 00:00

  • PCR13 Adherence to Anti-VEGF Treatment of Patients With Age-Related Macular Degeneration of Exudative Type (nAMD) and Diabetic Macular Edema (DME) in Gree Evidence From an Expert Panel

    Dec 1, 2025, 00:00

  • CO123 Fezolinetant Veoza™ As a Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms in Postmenopausal Women: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EE111 Budget Impact of Nivolumab Plus Ipilimumab Plus Chemotherapy as First-Line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer in Switzerland

    Dec 1, 2025, 00:00

  • EPH6 A Real-World Study on Italian Administrative Healthcare Data to Describe Patients With Chronic Obstructive Pulmonary Disease by Therapeutic Pattern and Exacerbation Rate

    Dec 1, 2025, 00:00

  • EE342 Does Modeling Adherence Matter? Insights From Prior NICE Appraisals

    Dec 1, 2025, 00:00

  • CO159 Lipid-Lowering Prescription Patterns After a Nonfatal Acute Coronary Syndrome: The Impact of Real-World Evidence on Clinical Practice With LATINO-ACS 2.0

    Dec 1, 2025, 00:00

  • CO68 Data Visualization of Treatment Patterns in Adults With BRAFV600E Mutant mNSCLC in Real-World Settings

    Dec 1, 2025, 00:00

  • EE440 Evaluating the Economic Benefit of Improved High-Dose Influenza Vaccine Coverage in the Elderly Population of Tokyo, Japan

    Dec 1, 2025, 00:00

  • HSD75 Modeling the Anticipated Organizational Impact on Health Service Provision of the Introduction of Tirbanibulin for the Topical Treatment of Actinic Keratosis in Fran EPIKA Study

    Dec 1, 2025, 00:00

  • RWD156 Real-World Evidence Study on Healthcare Resource Utilization (HCRU) Among Cancer Patients in the Helsinki and Uusimaa (HUS) Region, Finland

    Dec 1, 2025, 00:00

  • P59 Challenges in Assessing Trade-offs Between Efficiency and Equity in the Use of Digital Health Applications for Stroke Care

    Dec 1, 2025, 00:00

  • EE573 Markov Model-Based Cost-Effectiveness Evaluation of ROSA® vs. Manual Total Knee Arthroplasty: Sweden Payer Perspective

    Dec 1, 2025, 00:00

  • P61 Utilizing LLMs to Enhance Patient-Reported Outcome Measures: Application to the EQ-5D and Bolt-ons

    Dec 1, 2025, 00:00

  • HPR170 Real-World Data for External Controls: Insights From EMA Regulatory Submissions

    Dec 1, 2025, 00:00

  • EE548 Incorporating Environmental Impact Into Health Economic Evaluations: A Review of Methodological Approaches and Practical Applications

    Dec 1, 2025, 00:00

  • CO48 Clinical Outcomes Associated With Pembrolizumab Immunotherapy in Mesothelioma: A Systematic Review

    Dec 1, 2025, 00:00

  • HPR151 Optimizing Healthcare Systems in the MENA Region: Insights From Tailored Reimbursement for Innovative and Generic Essential Remedies (TRIGER) Meetings in Saudi Arabia and Algeria

    Dec 1, 2025, 00:00

  • CO194 Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Illness Among High-Risk Adults Aged 18-59 Years in Germany

    Dec 1, 2025, 00:00

  • SA69 Methods for the Economic Evaluation of Health Impacts of Climate Action: When, Why, and How Best to Use Them? A Literature Review

    Dec 1, 2025, 00:00

  • HTA287 Reimbursement Trends for GLP-1s and Emerging Antiobesity Drugs Across Seven Global Markets

    Dec 1, 2025, 00:00

  • RWD26 Burden of Duchenne Muscular Dystrophy in Italy: A Multicenter Cost of Illness Study

    Dec 1, 2025, 00:00

  • EE560 Introducing the Parameter Outcome Overview Plot: A New Addition to the Sensitivity Analysis Armory for Economic Models

    Dec 1, 2025, 00:00

  • CO64 Correlation Between Extension Survival Benefits and Incremental Costs of Oncology Drugs in Portugal: A Cross-Sectional, Regression Analysis

    Dec 1, 2025, 00:00

  • EE241 Cost-Effectiveness of ColonFlag in Austria: A Model-Based Evaluation

    Dec 1, 2025, 00:00

  • PCR152 Mapping the Rare Disease Diagnostic Odyssey of Today: An Adapted Targeted Literature Review (ATLR)

    Dec 1, 2025, 00:00

  • CO111 Evaluating Therapeutic Landscape in Radio-Iodine-Refractory–Differentiated Thyroid Cancer (DTC): A Bayesian Network Meta-Analysis of Clinical Efficacy

    Dec 1, 2025, 00:00

  • HSD62 Improving Patient Flow and Multidisciplinary Coordination in Urothelial Carcinoma: Insights From Bulgarian Oncologists

    Dec 1, 2025, 00:00

  • EE293 Cost-Savings Assessment of Fitusiran Prophylaxis in Minimizing Breakthrough Bleeding Treatment Expenses in the United Arab Emirates

    Dec 1, 2025, 00:00

  • HTA233 Middle East NICE Move Towards Standardized Health Technology Assessment

    Dec 1, 2025, 00:00

  • EPH211 Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy Patients in the Brazilian Public Health System: A Real-World Study

    Dec 1, 2025, 00:00

  • PCR113 Health-Related Quality of Life Among People With Arthritis in Ireland

    Dec 1, 2025, 00:00

  • HPR105 From Promise to Practi Addressing the Systemic Challenges of Underinvestment in Prevention

    Dec 1, 2025, 00:00

  • PCR153 Meaningful Within-Patient Change of the IWQOL-Lite-CT Physical Function Composite in Adults With Obesity

    Dec 1, 2025, 00:00

  • EE491 Health Economic Evaluation Model for Pancreatic Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • HTA308 Synthesizing Health Service Utilization Data for a Complex Intervention: A Case Study of Teledermatology

    Dec 1, 2025, 00:00

  • EE2 A Budget Impact Analysis of Exclusive Human Milk Diet in Very Low Birth Weight Infants in Sheikh Shakhbout Medical City

    Dec 1, 2025, 00:00

  • EE735 Treatment Patterns and Economic Outcomes in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US: A Real-World Claims Database Analysis

    Dec 1, 2025, 00:00

  • RWD106 Influencing Factors on the Health-Related Quality of Life of Middle-Aged and Elderly People in Ethnic Minority Areas of China: An Analysis Based on the Survey in a Urban Community of Guangxi Province

    Dec 1, 2025, 00:00

  • EE84 Budget Impact Analysis of Eplerenone For the Management of Heart Failure With Reduced Ejection Fraction (HFrEF) in Italy

    Dec 1, 2025, 00:00

  • HTA283 Reference Framework, Key Decision-Making Factors, and the Impact of Critical Parameters on Listing Recommendations for Nononcologic Drugs for Rare Diseases Issued by Canadian HTA Bodies

    Dec 1, 2025, 00:00

  • HTA49 Associations of Product-Specific and Clinical Evidence Quality Characteristics With Health Technology Assessment Outcomes: A Quantitative Assessment of Appraisals for Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • RWD102 Improving Identification of Patients With Rare Diseases Through Indirect Linkage Between French Medico-Administrative Claims Database (SNDS) and National Rare Disease Registry (BNDMR) in Fran A Dual-Population Study

    Dec 1, 2025, 00:00

  • EE96 Budget Impact Analysis of STRIDE (Tremelimumab + Durvalumab) vs. Atezolizumab + Bevacizumab for Unresectable Hepatocellular Carcinoma: Qatari Payer and Societal Perspectives

    Dec 1, 2025, 00:00

  • EE82 Budget Impact Analysis of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective

    Dec 1, 2025, 00:00

  • EE549 Incorporating Equity-of-Access Into Health Economic Evaluations: Surgical Task-Shifting for C-Sections in Sierra Leone

    Dec 1, 2025, 00:00

  • EPH265 Tropical Virus in Fran Dengue Cases on the Rise

    Dec 1, 2025, 00:00

  • HPR192 Ten Years of Portugal’s HTA System Through Stakeholder Eyes: Reflections and Future Priorities

    Dec 1, 2025, 00:00

  • MSR105 Exploring Perspectives on Adult Pneumococcal Vaccination: A Qualitative Preference Study of Healthcare Providers (HCPs) and Healthcare Consumers (HCCs) in the United Kingdom and Italy

    Dec 1, 2025, 00:00

  • SA97 Therapeutic Potential of Bispecific Antibodies in Adenocarcinoma: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • PCR42 Characterizing the UK Population Living With Von Willebrand Disease: Foundational Data for Health Economics and Outcomes Research

    Dec 1, 2025, 00:00

  • EE625 Quantifying the Economic Burden of Osteoarthritis in Portugal: Insights From a Patient Journey Model

    Dec 1, 2025, 00:00

  • HPR239 Which Country Is Currently Reporting the Lowest Global Prices for Semaglutide, and Why?

    Dec 1, 2025, 00:00

  • HTA43 Artificial Intelligence-Based Population, Intervention, Comparator, and Outcome (PICO) Prediction for European Union (EU) Joint Clinical Assessment (JCA)

    Dec 1, 2025, 00:00

  • CO3 A Systematic Literature Review and Network Meta-Analysis of Once-Weekly Icosema With Daily Fixed-Dose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment

    Dec 1, 2025, 00:00

  • EE280 Cost-Effectiveness of TEVAR With Active Control in Patients With TAA and TBAD: A Japanese Public Healthcare Payer Perspective

    Dec 1, 2025, 00:00

  • PCR83 Evaluating the Role of Disease-Specific Patient-Reported Outcomes in HTA Submissions for Rare Conditions: A Comparative Case Study of Narcolepsy and Phenylketonuria

    Dec 1, 2025, 00:00

  • HTA52 Barriers to Reimbursement: Characteristics of Unfunded Medicines in Ireland (2006-2021)

    Dec 1, 2025, 00:00

  • EE131 Clinical and Economic Impact of Hospital-Acquired Infections by Pseudomonas Aeruginosa in a Tertiary Care Teaching Hospital in India

    Dec 1, 2025, 00:00

  • HTA356 Viable Reimbursement and Financing Models for mHealth Interventions in Sub-Saharan Africa: A Narrative Review

    Dec 1, 2025, 00:00

  • PCR185 Perspectives of Patients and Caregivers on Relapsed/Refractory Acute Myeloid Leukemia Treatments: A Mixed-Methods Interview Study

    Dec 1, 2025, 00:00

  • HSD52 From Agricultural Waste to Clinical Value: An Economic and Operational Analysis of Paddy Straw-Based Utensils in Malaysian Hospital

    Dec 1, 2025, 00:00

  • CO5 A Systematic Review and Network Meta Analysis of Pharmacologic Disease-Modifying Therapies for Early Alzheimer's Disease

    Dec 1, 2025, 00:00

  • HTA278 Real-World Evidence (RWE) and Its Impact on Scottish Medicines Consortium (SMC) Decisions: A Retrospective Review

    Dec 1, 2025, 00:00

  • EE754 What Tips the Scale Toward Reimbursement? A Dutch-led Comparison of Pharmacoeconomic Evaluations Across the Netherlands, Sweden, and the United Kingdom

    Dec 1, 2025, 00:00

  • HTA319 The Impact of Clinical Evidence on the Inclusion of Non-Small Cell Lung Cancer Drugs in Brazil's Supplementary Healthcare System

    Dec 1, 2025, 00:00

  • HTA317 The Growing Role of Real-World Evidence (RWE) to Support Efficacy in EMA Oncology Approvals: Light at the End of the Tunnel

    Dec 1, 2025, 00:00

  • HPR132 Leveling the Field: How the MFN Could Transform Drug Pricing

    Dec 1, 2025, 00:00

  • EE722 The Role of Unpaid Work in Measuring the Social Costs of Disease

    Dec 1, 2025, 00:00

  • HTA123 Efficient and High-Quality Decision Making: An Exploration of Disease-Specific Reference Models at NICE

    Dec 1, 2025, 00:00

  • RWD104 Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia in United States Veterans

    Dec 1, 2025, 00:00

  • HPR61 Do Health Technology Assessments (HTA) Consider Racial Health Inequalities? A Case Study of NICE HTAs for Chronic Kidney Disease Hypertension and Diabetes

    Dec 1, 2025, 00:00

  • EPH166 Mortality in COPD and Cardiovascular Disease Comorbidity: Survival Analysis Using Curated Data From Brazilian Public Healthcare System (SUS)

    Dec 1, 2025, 00:00

  • MSR104 Exploring Nonproportional Hazards Multi-Level Network Meta-Regression (ML-NMR) for Survival Extrapolations in Oncology

    Dec 1, 2025, 00:00

  • EE415 Establishing Robust and Adaptive Willingness-to-Pay Thresholds for Taiwan's National Health Insuran A Case Study of Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • APPRAISE: A Tool for Appraising Potential for Bias in Real-World Evidence Studies on Medication Effectiveness or Safety

    Dec 1, 2025, 00:00

  • EE350 Economic and Clinical Impact of Older Adult Vaccination With the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico

    Dec 1, 2025, 00:00

  • RWD16 An AI-Powered Tool to Identify and Assess Fit-for-Use Registries for Drug Development and Evaluation

    Dec 1, 2025, 00:00

  • SA2 A Patient-Level Simulation to Bridge Data Gaps in Cost-Effectiveness Modeling of B-VEC for Dystrophic Epidermolysis Bullosa

    Dec 1, 2025, 00:00

  • HTA62 Budgetary Impact of Ultra-Rare Diseases in Brazil: A Review of Decisions From the Past Five Years

    Dec 1, 2025, 00:00

  • EE94 Budget Impact Analysis of Rozanolixizumab for the Treatment of Generalized Myasthenia Gravis (gMG) in Greece

    Dec 1, 2025, 00:00

  • EE553 Informing the Sustainable Development of Novel Therapies Using Value-Based Real Options Analysis

    Dec 1, 2025, 00:00

  • MSR75 AI Time and Motion - Analysis of the Accuracy and Efficiency of AI for HTA-Standard SLRs

    Dec 1, 2025, 00:00

  • MSR82 Efficacy and Safety of Modern Biologics Compared to Conventional Therapies in AQP-4 Positive Neuromyelitis Optica Spectrum Disorder: A Fully AI-Automated Targeted Literature Review

    Dec 1, 2025, 00:00

  • MSR8 A Novel Framework to Assess Noninferiority in National Institute for Health and Care Excellence (NICE) Cost-Comparison Evaluations (CCEs) Where Network Meta-Analyses (NMAs) Report Nonstatistically Significant Differences

    Dec 1, 2025, 00:00

  • EE299 Cost-Utility Analysis of AI-Assisted Ultrasound for Breast Cancer Detection in Taiwan

    Dec 1, 2025, 00:00

  • HPR93 Fair Pricing of Innovative Medicines From Definition to Application in CAR-T Cell Therapy

    Dec 1, 2025, 00:00

  • P46 Eliciting Preferences for Combination Vaccines Protecting Against Multiple Respiratory Viruses: A Cross-Sectional Discrete Choice Experiment of Adults Aged 50 in the US

    Dec 1, 2025, 00:00

  • MT30 Multi-Country Survey to Explore Clinicians Experiences on a New Imaging Technology for Gastrointestinal Endoscopes and Its Impact on Detection and Resection of Lesions

    Dec 1, 2025, 00:00

  • HTA71 Challenges in PICO Definition for HTDs: Lessons From Durvalumab Exercise

    Dec 1, 2025, 00:00

  • EE24 A Nonactive Implant for the Treatment of Chronic Gastro-esophageal Reflux Disease: A Cost-Effectiveness Evaluation From the Perspective of German Healthcare

    Dec 1, 2025, 00:00

  • HSD105 Subcutaneous vs. Intravenous Administration in Oncology: A Literature Review of Impacts on Patients, Providers, and Hospitals

    Dec 1, 2025, 00:00

  • PCR87 Evolution of High-Efficacy Therapies for Relapsing Multiple Sclerosis: Does Innovation Meet Patient Preferences?

    Dec 1, 2025, 00:00

  • HPR142 Mind the Gap: Exploring Variation in Guidelines for Indirect Treatment Comparison (ITC) Across Europe

    Dec 1, 2025, 00:00

  • EE547 Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions

    Dec 1, 2025, 00:00

  • EE345 Early Adoption of New Combination Biologic Therapy Enabled by Enhanced Diagnostic Accuracy in Inflammatory Bowel Disease (IBD) Can Be a Budget-Neutral Approach: A Budget Impact Analysis in Italy

    Dec 1, 2025, 00:00

  • EPH243 The Incidence and Survival of HPV-Positive and HPV-Negative Malignant Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States: A Surveillance Epidemiology and End Results SEER 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • MSR90 Evaluating an Automated AI-Driven Pipeline for Literature Surveillance and Synthesis: A Proof-of-Concept for Health Economics and Outcomes Research (HEOR) Communications

    Dec 1, 2025, 00:00

  • EPH230 The Changing Prevalence of Multicomorbid Patients in the US

    Dec 1, 2025, 00:00

  • EE731 Therapeutic Drug Monitoring and Selective Use of Glucarpidase in High-Dose Methotrexate Therapy: A Cost Analysis From the Algerian Payer Perspective

    Dec 1, 2025, 00:00

  • PT37 Economic Evaluation of I-Medicine: An AI-Driven E-Medicine Platform for Reducing Adverse Drug Reactions and Healthcare Expenditures

    Dec 1, 2025, 00:00

  • EE584 Modeling Early vs. Late Intervention Strategies: The Case of Dupilumab in Children With Severe Atopic Dermatitis

    Dec 1, 2025, 00:00

  • RWD183 Transplant Eligibility in DLBCL: A Real-World Analysis of German Hospital Billing Data

    Dec 1, 2025, 00:00

  • EE429 Estimation of Utility Weights for Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Covalent Bruton Kinase Inhibitor (cBTKi)

    Dec 1, 2025, 00:00

  • PCR237 The Mental Health Burden of Rare Diseases Based on Insights From Patients and Caregivers Through Rarepulse® Social Listening

    Dec 1, 2025, 00:00

  • HSD119 Understanding Trends and Opinions on More Environmentally Friendly Healthcare: A Clinician Survey

    Dec 1, 2025, 00:00

  • MSR221 What Is the Value of Large Language Models for Improving Extraction and Interpretation of Efficiency Data From French Commission Dévaluation Économique et de Santé Publique (CEESP): Decisions on Breast Cancer Medications?

    Dec 1, 2025, 00:00

  • EE577 Methodological Challenges for the Economic Evaluation of Genomic Newborn Screening: A Scoping Review

    Dec 1, 2025, 00:00

  • PT27 Synthetic Data Generation vs. Simulated Treatment Comparison: Assessment of the Performance of a Novel Approach for Unanchored Indirect Treatment Comparisons

    Dec 1, 2025, 00:00

  • EE340 Do We Need to Measure Social Impact of Innovative Drugs?

    Dec 1, 2025, 00:00

  • RWD159 Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data

    Dec 1, 2025, 00:00

  • MSR18 AI Assistant Meets Human: Refining Methods for Research-Tailored AI Assistants to Support Global Product Strategy, Decision Making, and HEOR Impact

    Dec 1, 2025, 00:00

  • MT27 Impact of Companion Diagnostics (CDx) on Reimbursement Outcomes of Breast Cancer and NSCLC Therapies

    Dec 1, 2025, 00:00

  • HTA213 Italian Perspective on Rare Disease New Treatments and HTA: Insights From Iptacopan Multidimensional Evaluation in PNH

    Dec 1, 2025, 00:00

  • HTA368 When Less Is More? Learnings From a Recent NICE Submission Utilizing a Novel Predictive Individual-Level Surrogacy Approach to Predict Overall Survival (OS) in the Absence of Trial-Level Evidence

    Dec 1, 2025, 00:00

  • MSR93 Evaluating the Efficacy of Artificial Intelligence Models as Suitable Screening Tools in Systematic Reviews: The Example of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure Treatment

    Dec 1, 2025, 00:00

  • PCR192 Productivity Impacts and the Need for Carer Support in Obstructive HCM: A Patient and Carer Survey

    Dec 1, 2025, 00:00

  • PCR163 Multiple Myeloma Caregiver Costs and Disabilities Data for Economic Modeling and HTA Submissions

    Dec 1, 2025, 00:00

  • HPR76 Evaluating the Effectiveness of Interventions to Reduce Gender Disparities in Healthcare: An Overview of Literature Reviews

    Dec 1, 2025, 00:00

  • EE70 Avacopan in the Treatment of ANCA-Associated Vasculitis: A Cost-Utility Analysis in Portugal

    Dec 1, 2025, 00:00

  • MSR110 Flexible Parametric Inference for Cause-Specific Hazard-Competing Risk Models Under Interval Censoring

    Dec 1, 2025, 00:00

  • MSR200 The Natural History of Pancreatic Cancer and the Effectiveness of Screening a Model-Based Analysis

    Dec 1, 2025, 00:00

  • EE174 Cost Implications of Declining MMR Coverage in England: Modeling NHS Burden and the Value of Catch-Up Vaccination

    Dec 1, 2025, 00:00

  • HTA218 Lessons Learnt From PICO Exercise Developed by the Joint Clinical Assessment Subgroup for Etranacogene Dezaparvovec

    Dec 1, 2025, 00:00

  • HTA250 Navigating Uncharted Waters: Challenge of Anticipating Technologies Subject to Environmental Considerations in Future HTA

    Dec 1, 2025, 00:00

  • CO152 Inefficiencies of Off-Label Therapy in the Prevention of Generalized Pustular Psoriasis (GPP) Flares: Real-World Evidence From Europe

    Dec 1, 2025, 00:00

  • HPR10 A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia

    Dec 1, 2025, 00:00

  • MSR26 An Update on the Evolving Use of Artificial intelligence and Machine Learning (AI/ML) in Systematic Literature Reviews (SLRs)

    Dec 1, 2025, 00:00
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »